Medifast (MED) Stock Forecast, Price Target & Predictions
MED Stock Forecast
Medifast stock forecast is as follows: an average price target of $83.75 (represents a 343.12% upside from MED’s last price of $18.90) and a rating consensus of 'Hold', based on 3 wall street analysts offering a 1-year stock forecast.
MED Price Target
The average price target for Medifast (MED) is $83.75 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $150.00 to $17.50. This represents a potential 343.12% upside from MED's last price of $18.90.
MED Analyst Ratings
According to 3 Wall Street analysts, Medifast's rating consensus is 'Hold'. The analyst rating breakdown for MED stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 2 'Hold' (66.67%), 1 'Sell' (33.33%), and 0 'Strong Sell' (0.00%).
Medifast Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jun 05, 2024 | Linda Bolton Weiser | D.A. Davidson | $17.50 | $23.97 | -26.99% | -7.41% |
| Apr 30, 2024 | Linda Bolton Weiser | D.A. Davidson | $25.00 | $35.51 | -29.60% | 32.28% |
| Jun 05, 2023 | Stephanie Wissink | Jefferies | $150.00 | $81.22 | 84.68% | 693.65% |
| Apr 06, 2023 | Linda Bolton Weiser | D.A. Davidson | $94.00 | $96.39 | -2.48% | 397.35% |
The latest Medifast stock forecast, released on Jun 05, 2024 by Linda Bolton Weiser from D.A. Davidson, set a price target of $17.50, which represents a -26.99% decrease from the stock price at the time of the forecast ($23.97), and a -7.41% decrease from MED last price ($18.90).
Medifast Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | 2 |
| Avg Price Target | - | - | $21.25 |
| Last Closing Price | $18.90 | $18.90 | $18.90 |
| Upside/Downside | -100.00% | -100.00% | 12.43% |
In the current month, the average price target of Medifast stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Medifast's last price of $18.90. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 22, 2023 | Citigroup | Hold | Hold | Hold |
| Jun 21, 2023 | Citigroup | Neutral | Neutral | Hold |
| Nov 04, 2022 | Redburn Partners | - | Sell | Initialise |
| Aug 04, 2022 | Jefferies | - | Hold | Downgrade |
Medifast's last stock rating was published by Citigroup on Sep 22, 2023. The company gave MED a "Hold" rating, the same as its previous rate.
Medifast Financial Forecast
Medifast Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $235.87M | $296.19M | $348.98M | $337.25M | $390.40M | - | $417.60M | $377.83M | $413.39M | $394.19M | $340.67M | $264.91M | $271.47M | $220.00M | $178.46M | $170.63M | $190.06M | $187.10M | $165.88M | $145.84M | $139.24M |
| Avg Forecast | $138.90M | $137.45M | $143.25M | $136.30M | $129.95M | $134.15M | $174.05M | $173.45M | $184.17M | $232.10M | $270.20M | $319.52M | $330.07M | $349.30M | $455.00M | $403.27M | $375.79M | $405.67M | $359.53M | $278.89M | $249.22M | $240.63M | $191.75M | $165.71M | $161.68M | $195.15M | $182.25M | $154.65M | $135.75M | $139.24M |
| High Forecast | $139.57M | $138.12M | $143.94M | $136.96M | $130.58M | $134.80M | $174.89M | $174.29M | $185.06M | $234.20M | $271.51M | $321.07M | $331.67M | $350.99M | $455.00M | $417.73M | $389.27M | $420.22M | $372.43M | $288.89M | $258.16M | $249.26M | $198.63M | $171.65M | $167.47M | $202.15M | $188.79M | $160.20M | $162.90M | $167.09M |
| Low Forecast | $138.23M | $136.78M | $142.56M | $135.64M | $129.32M | $133.50M | $173.21M | $172.61M | $183.28M | $230.00M | $268.89M | $317.97M | $328.47M | $347.61M | $455.00M | $388.80M | $362.31M | $391.11M | $346.64M | $268.88M | $240.28M | $232.00M | $184.87M | $159.76M | $155.88M | $188.15M | $175.71M | $149.10M | $108.60M | $111.39M |
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.02% | 1.10% | 1.09% | 1.02% | 1.12% | - | 1.04% | 1.01% | 1.02% | 1.10% | 1.22% | 1.06% | 1.13% | 1.15% | 1.08% | 1.06% | 0.97% | 1.03% | 1.07% | 1.07% | 1.00% |
Medifast's average Quarter revenue forecast for Dec 23 based on 1 analysts is $184.17M, with a low forecast of $183.28M, and a high forecast of $185.06M. MED's average Quarter revenue forecast represents a -21.92% decrease compared to the company's last Quarter revenue of $235.87M (Sep 23).
Medifast EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| EBITDA | - | - | - | - | - | - | - | - | - | $25.51M | $42.07M | $56.48M | $35.59M | $50.99M | - | $57.53M | $46.20M | $57.73M | $63.91M | $54.88M | $39.90M | $46.45M | $30.04M | $25.39M | $20.48M | $22.11M | $29.29M | $26.40M | $21.45M | $19.02M |
| Avg Forecast | $18.61M | $18.41M | $19.19M | $18.26M | $17.41M | $17.97M | $23.32M | $68.97M | $24.67M | $31.09M | $36.20M | $62.70M | $44.22M | $49.67M | $60.96M | $57.00M | $41.75M | $45.15M | $51.18M | $40.19M | $40.20M | $37.92M | $27.85M | $15.26M | $10.31M | $22.12M | $28.36M | $23.38M | $19.52M | $18.66M |
| High Forecast | $18.70M | $18.50M | $19.28M | $18.35M | $17.49M | $18.06M | $23.43M | $82.77M | $24.79M | $31.38M | $36.37M | $75.25M | $44.43M | $59.60M | $60.96M | $68.40M | $50.10M | $54.18M | $61.41M | $48.22M | $48.24M | $45.51M | $33.42M | $18.32M | $12.37M | $26.54M | $34.04M | $28.05M | $23.42M | $22.39M |
| Low Forecast | $18.52M | $18.32M | $19.10M | $18.17M | $17.32M | $17.88M | $23.20M | $55.18M | $24.55M | $30.81M | $36.02M | $50.16M | $44.00M | $39.73M | $60.96M | $45.60M | $33.40M | $36.12M | $40.94M | $32.15M | $32.16M | $30.34M | $22.28M | $12.21M | $8.25M | $17.69M | $22.69M | $18.70M | $15.61M | $14.93M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.82% | 1.16% | 0.90% | 0.80% | 1.03% | - | 1.01% | 1.11% | 1.28% | 1.25% | 1.37% | 0.99% | 1.23% | 1.08% | 1.66% | 1.99% | 1.00% | 1.03% | 1.13% | 1.10% | 1.02% |
1 analysts predict MED's average Quarter EBITDA for Dec 23 to be $24.67M, with a high of $24.79M and a low of $24.55M. This is -3.28% lower than Medifast's previous annual EBITDA (Sep 23) of $25.51M.
Medifast Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| Net Income | - | - | - | - | - | - | - | - | - | $23.13M | $30.28M | $39.97M | $26.52M | $36.16M | - | $41.78M | $34.02M | $41.98M | $46.96M | $41.06M | $27.99M | $34.45M | $21.93M | $18.48M | $19.88M | $15.90M | $21.38M | $20.75M | $15.65M | $13.78M |
| Avg Forecast | $1.09M | $-273.43K | $4.21M | $2.02M | $-2.02M | $-3.01M | $4.25M | $50.27M | $10.52M | $11.65M | $15.75M | $45.70M | $24.24M | $36.06M | $35.89M | $41.55M | $30.68M | $32.78M | $37.57M | $30.08M | $28.23M | $28.15M | $20.38M | $11.16M | $10.12M | $16.14M | $21.01M | $18.59M | $14.49M | $13.78M |
| High Forecast | $1.10M | $-271.70K | $4.24M | $2.04M | $-2.01M | $39.10M | $4.28M | $60.33M | $10.59M | $12.20M | $15.85M | $54.84M | $24.39M | $43.27M | $35.89M | $49.86M | $36.82M | $39.34M | $45.08M | $36.10M | $33.88M | $33.78M | $24.45M | $13.39M | $12.15M | $19.37M | $25.21M | $22.31M | $17.39M | $16.54M |
| Low Forecast | $1.09M | $-275.15K | $4.18M | $2.01M | $-2.04M | $-45.12M | $4.22M | $40.22M | $10.46M | $11.21M | $15.65M | $36.56M | $24.08M | $28.85M | $35.89M | $33.24M | $24.55M | $26.22M | $30.06M | $24.07M | $22.58M | $22.52M | $16.30M | $8.92M | $8.10M | $12.91M | $16.81M | $14.88M | $11.59M | $11.02M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.99% | 1.92% | 0.87% | 1.09% | 1.00% | - | 1.01% | 1.11% | 1.28% | 1.25% | 1.37% | 0.99% | 1.22% | 1.08% | 1.66% | 1.96% | 0.99% | 1.02% | 1.12% | 1.08% | 1.00% |
Medifast's average Quarter net income forecast for Dec 23 is $10.52M, with a range of $10.46M to $10.59M. MED's average Quarter net income forecast represents a -54.50% decrease compared to the company's last Quarter net income of $23.13M (Sep 23).
Medifast SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| SG&A | - | - | - | - | - | - | - | - | - | $151.87M | $172.01M | $192.88M | $201.00M | $234.69M | - | $247.20M | $231.45M | $251.89M | $232.27M | $195.75M | $161.27M | $159.48M | $131.20M | $111.71M | $109.36M | $122.67M | $113.36M | $100.43M | $89.29M | $89.73M |
| Avg Forecast | $84.13M | $83.25M | $86.76M | $82.55M | $78.71M | $81.25M | $105.42M | $105.06M | $111.55M | $140.58M | $163.65M | $270.40M | $199.91M | $216.35M | $275.58M | $245.81M | $208.74M | $196.68M | $185.82M | $143.41M | $162.63M | $130.30M | $121.88M | $67.44M | $55.69M | $124.50M | $111.38M | $90.00M | $82.65M | $89.73M |
| High Forecast | $84.54M | $83.65M | $87.18M | $82.95M | $79.09M | $81.65M | $105.93M | $105.56M | $112.09M | $141.85M | $164.45M | $324.47M | $200.88M | $259.62M | $275.58M | $294.98M | $250.49M | $236.01M | $222.98M | $172.09M | $195.15M | $156.37M | $146.26M | $80.93M | $66.83M | $149.40M | $133.65M | $108.00M | $99.18M | $107.68M |
| Low Forecast | $83.72M | $82.85M | $86.34M | $82.15M | $78.33M | $80.86M | $104.91M | $104.55M | $111.01M | $139.31M | $162.86M | $216.32M | $198.95M | $173.08M | $275.58M | $196.65M | $166.99M | $157.34M | $148.65M | $114.72M | $130.10M | $104.24M | $97.50M | $53.96M | $44.55M | $99.60M | $89.10M | $72.00M | $66.12M | $71.79M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.08% | 1.05% | 0.71% | 1.01% | 1.08% | - | 1.01% | 1.11% | 1.28% | 1.25% | 1.37% | 0.99% | 1.22% | 1.08% | 1.66% | 1.96% | 0.99% | 1.02% | 1.12% | 1.08% | 1.00% |
Medifast's average Quarter SG&A projection for Dec 23 is $111.55M, based on 1 Wall Street analysts, with a range of $111.01M to $112.09M. The forecast indicates a -26.55% fall compared to MED last annual SG&A of $151.87M (Sep 23).
Medifast EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 19 | Mar 19 | Dec 18 | Sep 18 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | 1 | - | - | 1 | 2 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 9 | 9 | 20 | 18 |
| EPS | - | - | - | - | - | - | - | - | - | $2.12 | $2.78 | $3.68 | $2.42 | $3.30 | - | $3.62 | $2.91 | $3.59 | $4.00 | $3.49 | $2.38 | $2.93 | $1.86 | $1.57 | $1.71 | $1.36 | $1.80 | $1.75 | $1.32 | $1.15 |
| Avg Forecast | $0.10 | $-0.03 | $0.39 | $0.18 | $-0.18 | $-0.28 | $0.39 | $0.80 | $0.96 | $1.06 | $1.44 | $2.40 | $2.22 | $1.91 | $3.27 | $3.57 | $2.65 | $3.08 | $3.32 | $2.73 | $2.38 | $2.46 | $1.83 | $1.33 | $1.07 | $1.34 | $1.72 | $1.54 | $1.12 | $1.14 |
| High Forecast | $0.10 | $-0.02 | $0.39 | $0.19 | $-0.18 | $3.58 | $0.39 | $0.81 | $0.97 | $1.12 | $1.45 | $2.42 | $2.23 | $1.92 | $3.27 | $3.74 | $2.78 | $3.22 | $3.47 | $2.85 | $2.49 | $2.57 | $1.92 | $1.39 | $1.13 | $1.40 | $1.80 | $1.61 | $1.34 | $1.37 |
| Low Forecast | $0.10 | $-0.03 | $0.38 | $0.18 | $-0.19 | $-4.13 | $0.39 | $0.80 | $0.96 | $1.02 | $1.43 | $2.38 | $2.20 | $1.90 | $3.27 | $3.40 | $2.53 | $2.94 | $3.16 | $2.60 | $2.27 | $2.34 | $1.75 | $1.26 | $1.02 | $1.28 | $1.64 | $1.47 | $0.90 | $0.91 |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.99% | 1.93% | 1.53% | 1.09% | 1.73% | - | 1.01% | 1.10% | 1.17% | 1.21% | 1.28% | 1.00% | 1.19% | 1.02% | 1.18% | 1.59% | 1.02% | 1.04% | 1.14% | 1.18% | 1.01% |
According to 1 Wall Street analysts, Medifast's projected average Quarter EPS for Dec 23 is $0.96, with a low estimate of $0.96 and a high estimate of $0.97. This represents a -54.61% decrease compared to MED previous annual EPS of $2.12 (Sep 23).
Medifast Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| MED | Medifast | $18.90 | $83.75 | 343.12% | Hold |
| MCW | Mister Car Wash | $6.56 | $10.00 | 52.44% | Buy |
| CSV | Carriage Services | $33.02 | $45.00 | 36.28% | Buy |
| ROL | Rollins | $50.47 | $52.25 | 3.53% | Buy |
| SCI | Service Corporation | $79.89 | $82.67 | 3.48% | Buy |
| BFAM | Bright Horizons Family Solutions | $140.68 | $116.20 | -17.40% | Hold |
| HRB | H&R Block | $63.20 | $33.30 | -47.31% | Sell |
MED Forecast FAQ
Is Medifast a good buy?
No, according to 3 Wall Street analysts, Medifast (MED) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of MED's total ratings.
What is MED's price target?
Medifast (MED) average price target is $83.75 with a range of $17.5 to $150, implying a 343.12% from its last price of $18.9. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Medifast stock go up soon?
According to Wall Street analysts' prediction for MED stock, the company can go up by 343.12% (from the last price of $18.9 to the average price target of $83.75), up by 693.65% based on the highest stock price target, and down by -7.41% based on the lowest stock price target.
Can Medifast stock reach $30?
MED's average twelve months analyst stock price target of $83.75 supports the claim that Medifast can reach $30 in the near future.
What are Medifast's analysts' financial forecasts?
Medifast's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $611.6M (high $614.56M, low $608.64M), average EBITDA is $127.67M (high $141.75M, low $113.59M), average net income is $49.49M (high $101.69M, low $-2.711M), average SG&A $370.43M (high $372.23M, low $368.64M), and average EPS is $0.731 (high $4.59, low $-3.128). MED's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $555.9M (high $558.59M, low $553.21M), average EBITDA is $74.47M (high $74.83M, low $74.11M), average net income is $7.05M (high $7.1M, low $7.01M), average SG&A $336.7M (high $338.33M, low $335.07M), and average EPS is $0.645 (high $0.649, low $0.641).
Did the MED's actual financial results beat the analysts' financial forecasts?
Based on Medifast's last annual report (Dec 2022), the company's revenue was $1.6B, beating the average analysts forecast of $1.54B by 3.96%. Apple's EBITDA was $195.79M, missing the average prediction of $211.85M by -7.58%. The company's net income was $143.57M, beating the average estimation of $137.73M by 4.24%. Apple's SG&A was $955.61M, beating the average forecast of $937.66M by 1.91%. Lastly, the company's EPS was $12.82, beating the average prediction of $10.97 by 16.85%. In terms of the last quarterly report (Sep 2023), Medifast's revenue was $235.87M, beating the average analysts' forecast of $232.1M by 1.62%. The company's EBITDA was $25.51M, missing the average prediction of $31.09M by -17.96%. Medifast's net income was $23.13M, beating the average estimation of $11.65M by 98.59%. The company's SG&A was $151.87M, beating the average forecast of $140.58M by 8.03%. Lastly, the company's EPS was $2.12, beating the average prediction of $1.06 by 99.06%